Table 1.
Adapted Newcastle-Ottawa Scale Items | High-quality items carrying a low risk of bias (green) | Low-quality items carrying a high (red) or an unknown (yellow) risk of bias |
Item 1: Representativeness of the initial study population - patients with GI bleeding and CKD/ESRD | All patients with upper or lower GI bleeding and CKD/ESRD were included. | Low: any selection criteria were applied to the study population (e.g., only transplanted patients). |
Unknown: no data on selection process. | ||
Item 2: Representativeness of the initial study population - patients with GI bleeding without CKD/ESRD | All patients with upper or lower GI bleeding without CKD/ESRD included. | Low: any selection criteria were applied to the study population. |
Unknown: no data on selection process. | ||
Item 3: Ascertainment of exposure | We defined chronic renal failure as present when eGFR was < 60 mL/min at least 3 mo. We defined end-stage renal disease as a condition where hemodialysis or chronic peritoneal dialysis is performed at least for 3 mo. | Low: CKD or ESRD is not present in all of the patients. |
Unknown: no definitions of the conditions mentioned are provided. | ||
Item 4: Comparability of cohorts A | Study controls for age: no significant difference was detected. | Low: significant difference was detected. |
Unknown: no statement. | ||
Item 5: Comparability of cohorts B | Study controls for taking ulcerogenic drugs: no significant difference was detected | Low: significant difference was detected between taking ulcerogenic drugs. |
Unknown: no comparison made by taking ulcerogenic drugs. | ||
Item 6: Follow-up time for rebleeding | The follow-up time is clearly defined. | Low: incomplete follow-up |
Unknown: no follow-up time is mentioned. |
CKD: Chronic kidney disease; ESRD: End-stage renal disease.